Drug Profile


Alternative Names: SYR-472; SYR111472 succinate; TAK-472; Trelagliptin succinate; Zafatek

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator PPD; Syrrx Inc
  • Developer 3SBio; Takeda
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 01 Dec 2016 Takeda completes a phase-III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (PO) (NCT02324569)
  • 31 Jul 2015 3SBio files an IND application with the China FDA in China for Type-2 diabetes mellitus
  • 28 Jul 2015 Takeda plans a phase III trial for Diabetes mellitus (with severe or end-stage renal failure) in Japan (NCT02512068)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top